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Evaluation of anti-Bothrops asper venom activity of ethanolic 
extract of Brownea rosademonte leaves
Significant inhibition of the coagulant and hemorrhagic ef-
fects of Bothrops asper venom was demonstrated by ethano-
lic extract prepared from the leaves of Brownea rosademonte. 
In vitro experiments preincubating 5.5 mg of extract kg–1 
b.m. for 30 min with a minimum hemorrhagic dose of ven-
om (273.8 ± 16.1 µg of venom kg–1 b.m.) lowered the hemorrha­
gic activity of the venom alone in CD­1 mice by 51.5 ± 2.6 %. 
Additionally, 1.7 mg extract L–1 plasma prolonged 5.1 times 
the plasma coagulation time. Fractionation of the extract 
led to the isolation of two compounds: ononitol (1) and 
quercetrin (2). The structure of compounds 1 and 2 was 
esta blished by spectroscopic analyses, including APCI­HR­
MS and NMR (1H, 13C, HSQC, HMBC and COSY). A quer-
cetrin concentration of 0.11 mmol L–1 prolonged the plasma 
coagulation time 2.6 times demonstrating that this com-
pound was one of the active constituents of the Brownea 
rosademonte extract.
Keywords: Bothrops asper (Viperidae) venom, Brownea rosade-
monte (Caesalpinaceae), quercetrin, anticoagulant, anti he­
mor rha gic, antiproteolytic, antihemolytic
Snakebite is a neglected public health problem in many tropical and subtropical coun-
tries worldwide. Close to 5 million snakebites occur every year, resulting in up to 2.5 mil-
lion snakebite poisonings. Deaths of at least 100,000, many amputations and other perma-
nent disabilities occur; most cases in Africa, Asia and Latin America. This health problem 
is often encountered among young people, children and farmers from poor rural settings 
with scarce medical resources (1–2).
Bothrops asper is mainly responsible (90 %) for snakebites in Panama (3), where about 
2500 of such accidents occur every year, and for the incidence of 76 new cases per 100,000 
inhabitants per year (4). Its venom induces conspicuous local effects (edema, hemorrhage, 
blisters, dermonecrosis, myonecrosis) and life­threatening systemic effects such as bleed-
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than 115 years after the beginning of serotherapy (7), antivenoms remain the only specific 
treatment for snakebites (8). Nevertheless, the lack of appropriate antivenom distribution 
and availability in distant rural places of tropical countries in Africa and Latin America 
has caused some snakebite victims to seek initial attention from traditional healers in their 
rural settings before their arrival to the hospital. Thus, they receive extracts of plants in 
many ways such as drinks, baths, steams and poultices, as reported by Otero et al. (9, 10) 
in Colombia. Plants could be a potential source for drug discovery in the treatment of ne-
glected tropical diseases like snakebites. A proof is that over 700 plants have been reported 
in folk medicine for treating snakebites (11). These plants are an invaluable source for ob-
taining compounds that could be useful to inhibit some of the toxic effects caused by 
snakebites. Unfortunately, only a few plants have been evaluated in controlled bioassays 
and information regarding the isolation of active principles is very limited (11). Further-
more, the kinetics of the absorption, distribution, metabolism and excretion of plant ex-
tracts as well as their concentration in the tissue, are still unknown (12). Finally, controlled 
clinical trials in humans, using those plants or their isolated compounds, are not run due 
to many ethical bans. 
In this work, an extract prepared from the leaves of Brownea rosademonte was tested for 
its neutralizing ability against the hemorrhagic, coagulant, hemolytic and proteolytic ef-
fects of B. asper venom from Panama.
EXPERIMENTAL
Animals and venom
CD­1 mice (50–70 days) weighing 18 to 19 g were used in the experiments. The animals 
were provided by the Biotery of the University of Panama (Panama City). The animals 
were kept in plastic cages under a 12 h light/12 h dark cycle at room temperature (23 ± 2 °C). 
The animals had free access to food and water. Experiments used the smallest possible 
number of animals and their suffering was avoided by using sevoflurane as general anes-
thetic. Animal care and the experimental protocol followed the international guiding prin-
ciples for biomedical research involving animals. 
Mice were divided into four groups of four mice (in duplicate) for use in hemorrhagic 
experiments as follows: group 1 (control mice treated only with venom), group 2 (mice 
treated only with plant extract), group 3 (control only with PBS), group 4 (mice treated with 
venom and plant extract). 
The experiments involved the hemorrhagic effect of venom and venom neutralization 
by the extract. B. asper venom was obtained by milking more than 90 adult specimens of 
B. asper from four different geographic regions of Panama. 
The venom was centrifuged at 3500 x g for 30 min, the supernatant was lyophilized and 
stored at –40 °C until used. Because of great similarity between B. asper and B. atrox venoms, 
the minimum inhibitory doses [minimum hemorrhagic dose (MHD), minimum coagulant 
dose (MCD), minimum indirect hemolytic dose (MIHD) and minimum proteolytic dose 
(MPD)] for each evaluated effect were determined based on the data previously reported 
for B. atrox venom (12–15). For the experiments, we used the respective reported minimum 
inhibitory doses plus two high and two low levels of venom (3, 2, 1, 0.5 and 0.3 MIHD). For 
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example, the previously reported MIHD was 0.13 mg L–1. So, to detect the MIHD of our 
venom we employed test concentrations of 0.39, 0.26, 0.13, 0.065 and 0.04 mg L–1.
It is important to clarify that experiments carried out to determine the antihemor-
rhagic effect of B. rosademonte on mice are considered to be in vitro because the crude plant 
extract was preincubated together with venom before being injected to test mice.
Plant collection and extract preparation
B. rosademonte (Caesalpiniaceae) leaves were collected in the Parque Nacional Alto Cha-
gres Panama; voucher specimens are deposited at the Herbarium of the University of 
Panama (Panama City, Panama). After sun drying fresh leaves and crushing them in a 
standard blender to obtain coarse powder, the extract was prepared by maceration with 
96 % ethanol for two days. Extract was concentrated to a semisolid paste using a rotary 
evaporator (Laborota 4010, Germany) to obtain 18.17 g of crude extract (6.2 % of plant yield) 
and stored at –4 °C until used.
Brine shrimp lethality assay
In vitro lethality assay of Artemia salina extract was used to detect cell toxicity. Brine 
shrimp eggs were placed in seawater [3.8 %, m/V, TetraMarine sea salt (United Pet Group, 
Inc., USA) in distilled water] and incubated at 28 °C. Eggs were hatched within 48 h provid-
ing a large number of larvae (nauplii). Ten nauplii were placed in each vial containing 5 mL 
of seawater and increasing concentrations of B. rosademonte extract (10, 50, 100, 500 and 1000 
µg mL–1). Each concentration was assessed in triplicate. Percentage of lethality was deter-
mined by comparing the mean number of surviving larvae of the test and control vials. LC50 
values were obtained from the best­fit line of plotted concentration vs. percentage of lethal-
ity. Potassium dichromate was used as a positive control in the bioassay while the negative 
control contained only the solvent (methanol) used for the preparation of test samples (16).
Antihemorrhagic activity of the extract
Groups were injected by intradermal route in the abdomen, one group with 5.5 mg of 
plant extract kg–1 b. m. (group 2) and the other with one MHD of venom (venom controls) 
(273.8 ± 16.1 µg of venom kg–1 b. m.) (group 1). In both cases, the solution was prepared in 
0.1 mL phosphate buffered saline (PBS), pH 7.2. The control group (group 3) received PBS 
alone under identical conditions. 
The plant extract (5.5 mg of extract kg–1 b. m.) was preincubated at 37 °C for 30 min 
with one MHD of B. asper venom (273.8 ± 16.1 µg venom kg–1 b. m.) dissolved in 0.1 mL PBS, 
pH 7.2. Then, the mixture was injected i.d. into four mice (group 4). Two hours later, mice 
were sacrificed by sevoflurane inhalation, and the diameter of the hemorrhagic area was 
measured (12).
Neutralization of the proteolytic activity of venom
Proteolytic activity of B. asper venom (10–250 µg mL–1) was examined according to the 
method of Lomonte and Gutierrez with slight modifications (12) using 1 % (m/V) casein as 
a substrate. For neutralization experiments, 800 mg of B. rosademonte extract was preincu-
bated for 30 min at 37 °C with one MPD (81 ± 5 U mg–1) of B. asper venom. Casein (2 mL) in 
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PBS pH 7.2 was then added to the mixture and again incubated for 30 min at 37 °C. The 
reaction was stopped by addition of 5 % trichloroacetic acid. The mixture was centrifuged 
at 3500xg for 10 min and absorbance of the supernatant was measured at 280 nm, in a 
Lambda 20 UV/VIS spectrometer (Perkin Elmer, USA). The experiment was repeated three 
times and results were expressed as mean ± SD.
Neutralization of indirect hemolytic activity of venom
The agarose­erythrocyte­egg yolk assay was used (14). Plant extract (25–1600 µg) was 
tested against one MIHD (195 ± 7 µg mL–1) of venom and the result was expressed as mean 
± SD. The experiments were perfomed in duplicate.
Neutralization of coagulant effect of venom 
Human plasma was used to assess the coagulant effect. Plasma was donated by the 
National Blood Bank (Panama City, Panama). The plasma came from healthy donors and 
complied with the Caja del Seguro Social (CSS, Panama National Hospital) requirements 
for use in biological experimentation and with permission from the donors. The method 
described by Theakston and Reid (18) was used with small modifications. Briefly, 1.0 µg of 
B. asper venom dissolved in 50 µL PBS, pH 7.2, was added to human plasma (0.3 mL), pre-
incubated at 37 °C and the time required for plasma coagulation was determined. To evalu­
ate the neutralizing capacity of the plant extract against the coagulant effect of venom, one 
MCD (1.7 µg mL–1) of B. asper venom was dissolved in 50 µL PBS, pH 7.2, and preincubated 
at 37 °C for 30 min with the plant extract (100 or 200 µg) and then, the mixture was added 
to human plasma (0.3 mL) and preincubated at 37 °C. The time required for plasma coagu-
lation was determined (15).
Chemical procedures
NMR spectra were acquired on a Jeol Eclipse 400 MHz spectrometer (Jeol, Japan) and 
referenced to residual solvent: 1H and 13C signals [dH 3.34, dC 49.86 for CD3OD and dH 2.54, 
dC 40.45 for (CD3)2SO]. APCIHR­MS were acquired on a JEOL LC­mate (Jeol) mass spec-
trometer.
Purification of the compounds was carried out by gel permeation column chromatog-
raphy using Sephadex LH­20 (Sigma­Aldrich, USA) and column chromatography on silica 
gel 60 (0.063–0.210 mm, Merck, Germany). TLC (analytical) was performed on precoated 
silica gel 60 F254 plates (Merck). All solvents were of analytical reagent grade (ACS) grade 
and were used without further purification. 
Extraction and isolation of ononitol and quercetrin from B. rosademonte extract
A portion of crude extract (10 g) was dissolved in a methanol/water mixture (90:10) and 
partitioned successively with ethyl acetate and hexane. All three fractions were evaporated 
to dryness using a rotar evaporator at low temperature (30 °C). Water fraction (2.5 g) was 
fractionated by gel permeation column chromatography using Sephadex LH­20 (50 g) and 
eluted with a methanol/water mixture (90:10, V/V) for three days, giving 36 fractions. A 
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major and active fraction (F4, 800 mg) was fractionated by column chromatography on sil-
ica gel 60 (50 g). The column was eluted with hexane, followed by a gradient of hexane/
CHCl3 (1:0→0:1) and finally with a gradient of CHCl3/methanol (1:0→1:1). Altogether, 10 
secondary fractions (FI to FX) were obtained. Because of the low yield and high complexity 
of fractions, we proceeded to work with major fractions only. From major fraction FIII elut-
ed with chloroform/methanol (8:2, V/V), 300 mg of ononitol (0.019 % of plant yield, com-
pound 1) was purified by re­crystallization (17). Fraction FVII (40 mg) was further subjected 
to silica gel 60 column chromatography and eluted with a gradient of hexane/chloroform 
(1:0→0:1) and chloroform/methanol (1:0→1:1). This process led to fifteen secondary fractions 
(F7­1 to F7­15). Fraction F7­9 eluted with 100 % ethyl acetate was filtered and 12.1 mg of 
quercetrin (0.007 % of plant yield, compound 2) was obtained in the supernatant (18).
RESULTS AND DISCUSSION
Looking for alternatives to combat snakebites in Panama, we have chosen the leaves 
of B. rosademonte to evaluate their properties against some B. asper venom toxic effects. This 
plant is used by traditional healers and in a previous study its stem bark extract showed in 
vitro neutralizing ability against the lethal, hemorrhagic, edema formating, defibrinating 
and coagulant effects of B. atrox asper venom (15).
As a first step, we evaluated the lethality of crude extract against brine shrimp (A. 
salina larvae) to verify the intrinsic toxicity of B. rosademonte. In the brine shrimp test, the 
plant extract showed an LC50 above 1000 µg mL–1, suggesting the absence of cytotoxicity. 
The next step was to find the MHD, MCD, MIHD and MPD of venom. The lowest dose of 
venom that induced a hemorrhagic area of 10 mm in diameter in 2 h (mean ± SD of three 
experiments) was 273.8 ± 16.1 µg venom kg–1 b. m. Furthermore, we found that the plant 
extract did not produce any hemorrhagic effect in mouse tissue, this being another sign of 
the harmlessness of the plant. The MIHD of B. asper venom was 195 ± 7 mg L–1. This dose 
induced a 20 mm diameter hemolysis halo after 20 h of incubation at 37 °C. MCD and MPD 
were 1.7 ± 0.2 µg mL–1 and 81 ± 5 U mg–1, respectively. 
Once the minimum doses were determined, we proceeded to evaluate the effect of the 
plant against those caused by snake venom and it was found that ethanolic extract from 
the leaves of B. rosademonte had significant in vitro activity against coagulant and hemor-
rhagic effects provoked by B. asper venom at 5.5 mg kg–1 b. m. significantly lowered 51.5 ± 
2.6 % the hemorrhagic activity of B. asper venom (Fig. 1) and at 1.7 mg extract L–1 plasma 
prolonged the plasma coagulation time induced by the venom until 5.1 times. This may 
indicate the possible inhibition of venom metalloproteinases responsible for local and sys-
temic hemorrhage, as well as the thrombin­like enzymes of venom responsible for plasma 
coagulation by this plant extract. Ethanolic extract significantly prolonged the plasma co-
agulation time when preincubated with the venom (one microgram of venom­induced 
coagulation of human plasma in 30.1 ± 1.5 s). This effect was dose­dependent because 1.7 
mg of extract L–1 of plasma showed a coagulation time of 155.3 ± 2.4 s, whereas 3.4 mg of 
extract L–1 plasma delayed the coagulation time to 350.4 ± 3.9 s (p < 0.001). Proteolytic and 
indirect hemolytic activities of B. asper venom were not neutralized by the ethanolic extract 
prepared from the leaves of B. rosademonte.
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Steroids, triterpenes, flavonoids and tannins were detected in the plant extract by TLC 
analysis (21).
Subsequent extract fractionation and compound purification were carried out by se­
veral chromatographic methods. These processes led isolation of two major components: 
ononitol (1) and quercetrin (2) from B. rosademonte (Fig. 2). 
Compound 1 was isolated as a colorless crystalline solid. Its molecular formula was 
determined as C7H15O6 by APCI­HR­MS. The 13C NMR spectrum for 1 (Table I) revealed 7 
resonances, interpreted from the multiplicity­edited HSQC and DEPT (135 and 90) data as 
six methane and one methyl group. The 1H NMR spectrum (Table I) showed three triplets 
(at dH 3.59, 3.57 and 3.30 ppm), two doublets of doublets (at dH 3.76, and 3.71 ppm), a quartet 
(at dH 4.08 ppm), and a singlet (at dH 3.62 ppm). This evidence suggested that compound 1 
was a cyclohexitol methyl ether. Based on detailed analysis of the spectroscopic data and 
Fig. 1. Determination of the hemorrhagic effect of B. asper venom before and after B. rosademonte leaf 
ethanol extract administration: a) control (PBS, pH 7.2, and DMSO); b) 1 MHD of B. asper venom (273.8 
± 16.1 µg of venom kg–1 b. m.); c) 5.5 mg of B. rosademonte extract kg–1 b. m.;  d) 1 MHD of B. asper 






























Fig. 2. Chemical structures of major compounds isolated from B. rosademonte.
a)                                    b)                                       c)                                    d)
481
M. Salazar et al.: Evaluation of anti­Bothrops asper venom activity of ethanolic extract of Brownea rosademonte leaves, Acta Pharm. 64 
(2014) 475–483.
 
comparison with the data reported by Vernon et al. (19), compound 1 was identified as 
ononitol.
Compound 2 was obtained as a yellow amorphous powder (m.p. 181–182 °C). The high 
resolution mass spectrum APCI (positive mode) showed a pseudo­molecular ion at m/z 
449.1079 [M + H]+, corresponding to the molecular formula C21H21O11. The 13C NMR spec-
trum (Table I) showed the presence of resonances characteristic of a flavonol core (dC 157.0, 
134.8, 178.1, 161.9, 99.2, 164.8, 94.3, 157.5, 104. 7, 121.6, 116.2, 149.0, 145.8, 116.0, 121.2 ppm). The 
1H NMR spectrum of 2 (Table I) showed two doublets at dH 6.21 and 6.40 ppm, indicating 
that the compound contained a 1,3 disubtituted aromatic ring A. Moreover, the resonan ces 
at dH 7.36, 7.30 and 6.87 ppm suggested the presence of a 1,3,4­trisubstituted aromatic ring 
B. In adition, two resonances at dH 5.25 (d, J = 1.5 Hz, H­1”) and 0.86 ppm (d, J = 5.6 Hz, H­6”) 
suggested the presence of a rhamnose unit in the structure of compound 2. Based on the 
above evidence, the structure of 2 was defined as quercetrin. The structure of compound 
Table I. NMR data for compounds isolated from B. rosademontea
Position
Ononitol  (in CD3OD) Quercetrin (in DMSO­d6)
13C 1H
1 83.6 3.59 (t, 9.4)
2 71.2 4.08 (q, 3.8) 157.0
3 70.7 3.71 (dd, 2.8) 134.8
4 72.4 3.30 (t, 9.4) 178.1
5 73.0 3.57 (t, 9.4) 161.9
6 72.1 3.76 (dd, 2.8) 99.2 6.21 (d, 2.2)
7 59.5 3.62 (s) 164.8




2’ 116.2 7.30 (d, 1.8)
3’ 149.0
4’ 145.8
5’ 116.0 6.87 (d, 8.4)
6’ 121.2 7.36 (dd, 8.1, 1.8)
1’’ 102.4 5.25 (d, 1.5)
2’’ 70.9 4.20 (m)
3’’ 71.2 3.73 (dd, 9.2, 3.4)
4’’ 70.6 3.31 (m)
5’’ 71.5 3.38 (m)
6’’ 18.1 0.90 (d, 6.6)
a Coupling constants (J in Hz) are given in brackets.
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2 was confirmed by comparing our experimental data with those reported by Hanamura 
et al. (20).
Compounds 1 and 2 (with approximately 98 % purity level) were tested against the 
hemorrhagic and coagulant activities of B. asper venom. Only compound 2 showed neu-
tralizing capacity against the coagulant effect of venom. A concentration of 0.11 µmol L–1 
of quercetrin prolonged the plasma coagulation time in the presence of 1 µg of venom 2.6 
times. Unfortunately, it was not possible to isolate other pure active compounds with the 
methodology used. However, we found out that highly polar fractions were those that 
showed the antihemorrhagic effect. This fact shows that highly hydroxylated compounds 
may be the main antihemorrhagic components of the plant.
CONCLUSIONS
Biological assessments performed with B. rosademonte ethanolic extract allowed us to 
demonstrate that this plant possesses significant activity in vitro against coagulant and 
hemorrhagic effects induced by B. asper venom. In the brine shrimp test, the organic extract 
of B. rosademonte showed no cytotoxicity (LC50 above 1000 µg mL–1). On the other hand, it 
was demonstrated that quercetrin is one of the major anti­coagulant compounds of that 
plant. To our knowledge, this is the first report on the isolation and structural characteriza-
tion of some compounds produced by Brownea rosademonte.
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